Usted buscó: enrollment (Inglés - Maltés)

prior to study enrollment, diagnosis of bcc was confirmed by histology.
qabel dħul fl-istudju, id-dijanjosi ta’ bcc kienet ikkonfermata permezz tal-istoloġija.

enrollment into the registry will continue until at least 150 patients have received prialt.
ir- reklutaġġ fir- reġistru ser jissokta sakemm mill- inqas 150 pazjent ikunu ħadu prialt.

the first interim analysis was planned 3 years after the date when half of study enrollment was done.
l-ewwel analisi temporanja ġiet ippjanata 3 snin wara d-data li fiha nofs il-pazjenti għall-istudju ġew irreġistrati.

four randomized controlled studies were performed in dialysis patients treated with darbepoetin alfa or epoetin at the time of enrollment.
erba ’ studji randomised ikkontrollati twettqu fuq pazjenti fuq dijalisi li kienu qed jiġu kkurati b’ darbepoetin alfa jew epoetin meta daħlu fl- istudju.

four randomized controlled studies were performed in dialysis patients currently treated with darbepoetin alfa or epoetin at the time of enrollment.
erba’ studji randomised ikkontrollati, twettqu fuq pazjenti fuq dijalisi li kienu qed jiġu kkurati b’darbepoetin alfa jew epoetin meta daħlu fl-istudju.

patients with hemodynamically significant congenital heart disease were excluded from enrollment in this study and were studied in a separate study.
pazjenti b’mard tal-qalb konġenitali emodinamikament sinifikanti kienu esklużi milli jieħdu sehem f’dan l-istudju u kienu studjati fi studju separat.

patients were randomized to stay on their treatment at thetime of enrollment or to be switched to mircera in order to maintain stable haemoglobin levels.
il- pazjenti kienu randomised biex jibqgħu fuq il - kura li kellhom meta daħlu fl- istudju jew biex jinqalbu għal mircera biex b’ hekk iżommu livelli stabbli ta ’ emoglobina.

subjects in the on-demand cohort had to have at least 12 documented bleeding episodes requiring treatment within 12 months prior to enrollment.
individwi fil-koorti ta' kura fil-pront kellu jkollhom mill-inqas 12-il episodju ta' ħruġ ta' demm iddokumentat li kienu jeħtieġu l-kura fi żmien it-12-il xahar qabel ir-reġistrazzjoni.

enrollment in arm 3 was discontinued, as pre-specified, once safety of avastin with the ifl regimen was established and considered acceptable.
kif is- sigurtà tad- dożaġġ ta ’ avastin ma ’ ifl ġiet stabbilita u kkunsidrata bħala aċċettabli, ma baqgħux jiddaħħlu pazjenti f’ kategorija 3 hekk kif kien speċifikat minn qabel.

during the first 3 hours post-enrollment, patients could supplement with bolus intravenous fentanyl given, as needed, to achieve comfort.
matul l-ewwel 3 sigħat wara r-reġistrazzjoni, il- pazjenti setgħu jissupplimentaw b’injezzjoni f’daqqa ta’ fentanyl mogħti ġol-vina, kif meħtieġ, biex iħossuhom sew.

across all three studies, patients reported receiving on average 4 to 6 medications (including h1 antihistamines) for csu symptoms prior to study enrollment.
fit-tliet studji kollha kemm huma, il-pazjenti rrappurtaw li ngħataw medja ta’ 4 u 6 medikazzjonijiet (inkluż antiistamini h1) għas-sintomi tas-csu qabel ma ssieħbu fl-istudju.

enrollment in the patient stratum with baseline calculated gfr below40 ml/min was discontinued due to an imbalance in safety events (see section 4.8).
ir-reġistrazzjoni fl-istratum tal-pazjenti bil-gfr ikkalkulat fil-linja bażi taħt 40 ml/min ġiet imwaqqfa minħabba żbilanċ f’okkorrenzi ta’ sigurtà (ara sezzjoni 4.8).

clinical studies with prevenar 13 currently provide immunogenicity data in adults aged 18 years and older, including adults aged 65 and older previously vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine, 5 years prior to enrollment.
bħalissa l-istudji kliniċi bi prevenar 13 jipprovdu dejta dwar l-immunoġeniċità fl-adulti li għandhom ’l fuq minn 18-il sena, inkluż adulti ’l fuq minn 65 sena li preċedentement tlaqqmu b’doża waħda jew aktar tal-vaċċin polisakkaride pnewmokokkali ta’ 23-valenti, 5 snin qabel l-istudju.

the results of ongoing study gtc at hd 012-04 and in particular the results of investigations in pregnant women treated during the peri-partum period will be submitted when enrollment is completed (total of 17 patients, a mix of surgical and pregnant women).
ir- rizultati ta 'studju gtc at hd 012- 04 li ghadu ghaddej, u b' mod partikulari, ir- rizultati ta' investigazzjonijiet f' nisa tqal ikkurati matul il- perjodu tal- peri- partum ser ikunu sottomessi meta titlesta r- registrazzjoni, (total ta '17 il- pazjent, tahlita ta' nisa li kellhom operazzjoni u nisa tqal).